This is a prospective, randomized, double-blind, and controlled clinical study to investigate
the effects of DLBS1033 in conjunction with standard therapy compared to standard therapy
alone in acute ischemic stroke patients. It is hypothesized that the improvement in
functional outcomes as measured by NIHSS and BI as well as the improvement in haemostatic
parameters as measured by thrombocyte aggregation test (TAT), fibrinogen, and d-dimer in DLBS
group will be significantly greater than those in the control group.